Perspective Therapeutics Names New Directors, CMO Departs
Ticker: CATX · Form: 8-K · Filed: Nov 3, 2025 · CIK: 728387
| Field | Detail |
|---|---|
| Company | Perspective Therapeutics, Inc. (CATX) |
| Form Type | 8-K |
| Filed Date | Nov 3, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $680,000, $451,500, $516,700 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, board-of-directors
TL;DR
Perspective Therapeutics is shaking up its leadership: CMO out, two new directors in.
AI Summary
Perspective Therapeutics, Inc. announced on November 3, 2025, the departure of its Chief Medical Officer, Dr. Michael L. Lavoie. The company also reported the election of two new directors, Dr. David J. E. J. M. Van Den Berg and Mr. David L. Schull, to its Board of Directors.
Why It Matters
Changes in key leadership roles and board composition can signal shifts in company strategy or operational focus, potentially impacting future performance and investor confidence.
Risk Assessment
Risk Level: medium — Changes in executive and board positions can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Perspective Therapeutics, Inc. (company) — Registrant
- Dr. Michael L. Lavoie (person) — Departing Chief Medical Officer
- Dr. David J. E. J. M. Van Den Berg (person) — Newly Elected Director
- Mr. David L. Schull (person) — Newly Elected Director
- November 03, 2025 (date) — Date of Report
FAQ
Who has departed from Perspective Therapeutics?
Dr. Michael L. Lavoie, the Chief Medical Officer, has departed from Perspective Therapeutics.
When was this report filed?
This report was filed on November 03, 2025.
Who are the newly elected directors?
Dr. David J. E. J. M. Van Den Berg and Mr. David L. Schull have been elected as new directors.
What is the company's primary business?
Perspective Therapeutics, Inc. is in the Pharmaceutical Preparations industry (SIC 2834).
What is the company's state of incorporation?
The company is incorporated in Delaware.
Filing Stats: 1,119 words · 4 min read · ~4 pages · Grade level 16.8 · Accepted 2025-11-03 16:30:24
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CATX NYSE American LLC
- $680,000 — Executive's current annual base salary ($680,000 for Mr. Spoor, $451,500 for Mr. Hunt an
- $451,500 — al base salary ($680,000 for Mr. Spoor, $451,500 for Mr. Hunt and $516,700 for Dr. Puhlm
- $516,700 — or Mr. Spoor, $451,500 for Mr. Hunt and $516,700 for Dr. Puhlmann), and (ii) revise cert
Filing Documents
- catx-20251103.htm (8-K) — 46KB
- 0001193125-25-262636.txt ( ) — 154KB
- catx-20251103.xsd (EX-101.SCH) — 25KB
- catx-20251103_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PERSPECTIVE THERAPEUTICS, INC. Date: November 3, 2025 By: /s/ Chris Nenno Chris Nenno General Counsel and Corporate Secretary